Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 12, 2021 09:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Investigational Hair Loss Therapeutic, OLX104C

SUWON, Republic of Korea, Aug. 12, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has received a...
August 04, 2021 09:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Announces Results from Preclinical Study of NASH Therapeutic Candidate

- OLX702A reversed liver tissue damage in mouse model of NASH - Results and additional pipeline updates across hair loss, AMD and HBV programs presented at 48th KAST International Symposium -...
June 14, 2021 10:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals to Present at 2021 RNAi-Based Therapeutics Summit

SUWON, Republic of Korea, June 14, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that June Hyun Park, Ph.D.,...
June 10, 2021 15:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals to Conduct One-on-One Meetings with Potential Partners at BIO Digital 2021 Conference

SUWON, Republic of Korea, June 10, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
June 09, 2021 10:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Signs Agreement with LGC Biosearch Technologies to Accelerate Production of Asymmetric siRNA for the Treatment of Androgenic Alopecia

SEOUL, Republic of Korea and LONDON, June 09, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, and LGC, a global leader in the life...
June 07, 2021 08:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Subsidiary mCureX Announces Business Agreements to Advance Development of mRNA Vaccines and Therapeutics

SUWON, Republic of Korea, June 07, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company’s subsidiary mCureX has...
May 24, 2021 08:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Improved Intracellular Delivery Platform Technology for RNAi Therapeutics

SUWON, Republic of Korea, May 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company has received a notice of...
February 10, 2021 17:45 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate

Company to discuss study results and present corporate overview at SMi’s 12th Annual RNA Therapeutics Virtual Conference on February 11 SUWON, Republic of Korea, Feb. 10, 2021 (GLOBE NEWSWIRE) --...
February 08, 2021 07:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Launches New Subsidiary to Develop mRNA Vaccines and Therapeutics

SUWON, Republic of Korea, Feb. 08, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, has announced the establishment of mCureX...
January 06, 2021 07:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals to Present at 2021 ICR Conference

SUWON, Republic of Korea, Jan. 06, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...